Bausch Health Reports Growth Amid Improved Financials
Company Announcements

Bausch Health Reports Growth Amid Improved Financials

Bausch Health Companies ( (BHC) ) has realeased its Q3 earnings. Here is a breakdown of the information Bausch Health Companies presented to its investors.

Bausch Health Companies Inc., a diversified global pharmaceutical firm, focuses on delivering healthcare solutions across gastroenterology, neurology, dermatology, and eye health. In its latest earnings report for the third quarter of 2024, Bausch Health announced a continuation of its growth trend, marking its sixth consecutive quarter of year-over-year revenue and adjusted EBITDA growth. The company’s consolidated revenues reached $2.51 billion, a 12% increase from the previous year, with notable growth in all segments. However, the firm reported a GAAP net loss of $85 million, though this was a substantial improvement from the $378 million loss recorded in the same quarter last year. Its adjusted EBITDA rose by 10% to $909 million, reflecting strong operational performance despite higher administrative costs and interest expenses. The company also raised its full-year 2024 guidance, indicating confidence in its continued growth trajectory. Looking ahead, Bausch Health remains committed to advancing its R&D pipeline and strengthening its financial standing, reflecting a cautious yet optimistic outlook for the future.

Related Articles
Casey Dylan, CIMABausch + Lomb (BLCO) Posts Impressive Revenue and Explores Potential Sale
TipRanks Canadian Auto-Generated NewsdeskBausch Health Reports Strong Growth in Q3 2024
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App